Company to Host Corporate Update Webinar Today, January 3, 2024, at 8:30 am ET-
-Interim Analysis of Phase 3 REGAL Study of Galinpepimut-S in Patients with Acute Myeloid Leukemia Expected in First Quarter 2024 -
- Phase 2a Study of SLS009 in Relapsed/Refractory AML Patients Ongoing with Topline Data Expected in First Quarter of 2024
- Phase 1b/2 Study in Relapsed/Refractory Peripheral T-cell Lymphoma Patients Ongoing with Top-line Data Expected in First Half 2024 –
| Webinar: | |
| Date: | Wednesday, January 3, 2024 |
| Time: | 8:30 a.m. Eastern Time |
| Dial-in (U.S.): | 1-877-423-9813 |
| International Dial-in: | 1-201-689-8573 |
| Webcast: | SELLAS Update Call |
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.